Barclays downgraded Tate & Lyle to Equal Weight from Overweight with a price target of 760 GBp, down from 950 GBp. The firm says GLP-1 drugs pose a “structural bear case” for food Ingredients stocks that is difficult to dismiss. A growing negative narrative around the health risks of ultra-processed foods could further pressure market expectations on terminal growth, the analyst tells investors in a research note. Barclays turned more cautious on the predominantly food-exposed ingredient names.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TATYY: